Table 1.
Prioritized targets with summary of information from cross-validation tables.
| Hallmark1,2 | Target (action on target) |
Contrary | Controversial | Complementary | None known |
|---|---|---|---|---|---|
| AP, RI, TPI | Akt (inhbit) | 0 | 0 | 11 | 0 |
| SPS | Androgen receptor signaling (suppress) | 0 | 2 | 8 | 1 |
| TIM | AP-1 (inhibit) | 1 RI | 0 | 7 | 3 |
| EAG | ARID1A (activate) | 1 TIM | 0 | 5 | 5 |
| AP | Bcl-2 (inhibit) | 0 | 1 | 9 | 1 |
| RI | CDK 1/2/5/9 (inhibit) | 1 TME | 0 | 9 | 1 |
| RI | CDK 4/6 (inhibit) | 1 GI | 1 | 8 | 1 |
| SPS | Cell cycle (CDKs/cyclins) (attenuate) | 2 IS, TIM | 0 | 9 | 0 |
| GI | Centrosome clustering (block) | 0 | 0 | 8 | 3 |
| TME | Cholesterol metabolites (inhibit) | 0 | 0 | 7 | 4 |
| TME | Cholesterol synthesis (inhibit) | 0 | 1 | 8 | 2 |
| TPI | COX-2 (inhibit) | 1 AN | 0 | 10 | 0 |
| TPI | CXC chemokine (inhibit) | 0 | 3 | 5 | 3 |
| AN | Disturbed circadian rhythms (normalize) | 0 | 2 | 9 | 0 |
| GI | DNA damage (prevent) | 1 TPI | 3 | 5 | 2 |
| GI | DNA repair (enhance) | 1 TPI | 3 | 5 | 2 |
| EAG, TIM | E-cadherin (restore) | 1 AN | 4 | 4 | 2 |
| EAG | E2F (inactivate) | 1 TME | 0 | 7 | 3 |
| AP | EGFR (inhibit) | 0 | 0 | 10 | 1 |
| AN | Elevated interstitial fluid pressure (reduce) | 0 | 0 | 9 | 2 |
| TME | Endoglin (inhibit) | 0 | 1 | 5 | 5 |
| AN | Endothelial cell migration/tip cell formation (inhibit) | 0 | 0 | 7 | 4 |
| AP | Enox (inhibit) (AP) | 0 | 0 | 5 | 6 |
| SPS | ER signaling (suppress) | 1 TIM | 3 | 7 | 0 |
| EAG | ER stress (induce) | 2 AN, TIM | 1 | 7 | 1 |
| TIM | FAK signaling (inhibit) | 0 | 0 | 9 | 2 |
| TME | Fibrosis (inhibit) | 0 | 0 | 6 | 5 |
| EAG | Growth differentiation factor 15 (induce) | 1 GI | 0 | 5 | 5 |
| SPS | HIF-1 signaling (inhibit) | 0 | 0 | 9 | 2 |
| AP | Hsp90 (inhibit) (AP) | 1 TIM | 0 | 8 | 2 |
| RI | hTERT (inhibit) | 0 | 1 | 8 | 2 |
| AN | Hypoxia (reduce) | 0 | 1 | 10 | 0 |
| TME | IDO (inhibit) | 0 | 1 | 7 | 3 |
| EAG, SPS | IGF-1R (inhibit) | 0 | 0 | 9 | 2 |
| IE | IL-12 (induce) | 1 AP | 0 | 5 | 5 |
| TME | IL-6 (inhibit) | 0 | 3 | 7 | 1 |
| TPI | iNOS (block) | 1 AN | 1 | 6 | 3 |
| TME | JAK (inhibit) | 0 | 0 | 10 | 1 |
| AN | Lymphangiogenesis (impede) | 0 | 1 | 4 | 6 |
| TME | M2 macrophage conversion (inhibit) | 0 | 0 | 7 | 4 |
| IE | Macrophages (activate) | 2 SPS, TIM | 2 | 3 | 4 |
| AP | Mcl-1 (inhibit) | 0 | 0 | 10 | 1 |
| TPI | MIF (block) | 0 | 0 | 9 | 2 |
| TIM | MMP-9 (suppress) | 0 | 1 | 7 | 3 |
| RI | mTOR (inhibit) | 0 | 2 | 8 | 1 |
| SPS, TIM, TPI | NF-KB signaling (inhibit) | 0 | 2 | 8 | 1 |
| IE | NK cell activity (promote) | 0 | 0 | 7 | 4 |
| EAG | NOTCH (block) | 1 AN | 0 | 8 | 2 |
| AP | Nuclear exporter CRM1 (inhibit) | 0 | 0 | 6 | 5 |
| RI | PI3K (inhibit) | 0 | 0 | 11 | 0 |
| EAG, SPS, TIM | PI3K/Akt signaling (inhibit) | 0 | 0 | 11 | 0 |
| AN | Poor perfusion (improve) | 0 | 1 | 7 | 3 |
| AP | Proteasome (inhibit) | 0 | 0 | 10 | 1 |
| TME | ROS (inhibit) | 0 | 2 | 7 | 2 |
| AN | Structural abnormalities of vessel walls (inhibit) | 0 | 0 | 7 | 4 |
| GI | Target deficient DNA repair | 1 TPI | 2 | 5 | 3 |
| GI, RI | Telomerase (inhibit) | 0 | 0 | 10 | 1 |
| TIM | TGF-β (inhibit) | 1 RI | 2 | 7 | 1 |
| IE | Th1 response (promote) | 1 TPI | 0 | 5 | 5 |
| TIM | Tight junctions (promote) | 1 AN | 0 | 6 | 4 |
| TPI | TNF-α (block) | 1 IE | 1 | 8 | 1 |
| IE | Treg lymphocytes (inhibit) | 0 | 1 | 6 | 4 |
| AP | Tumor autophagy (activate) | 1 TPI | 4 | 4 | 2 |
| AN | Tumor cell metabolism/acidosis (normalize) | 0 | 0 | 9 | 2 |
| AP | Tumor necrosis (activate) | 2 AN, TME | 3 | 5 | 1 |
| AN | Tumor-promoting fibro-blasts (deactivate) | 0 | 0 | 9 | 2 |
| AN | Tumor-promoting inflammation (suppress) | 0 | 0 | 7 | 4 |
| TIM | Urokinase plasminogen activator (suppress) | 1 RI | 0 | 7 | 3 |
| TME | VEGF (inhibit) | 0 | 3 | 8 | 0 |
| EAG | Wildtype p53 (upregulate) | 0 | 0 | 10 | 1 |
| SPS | Wnt (B-catenin) (inhibit) | 0 | 3 | 7 | 1 |
| EAG | YAP/TEAD activity (inhibit) | 0 | 0 | 6 | 5 |
| TIM | β-catenin/ZEB1 (inactivate) | 0 | 0 | 7 | 4 |
| IE | γδ T-cell activity (promote) | 2 TPI, AN | 0 | 4 | 5 |
| Totals: | 32 | 62 | 543 | 177 | |
| Percentages: | 3.93% | 7.62% | 66.71% | 21.74% |
For each target, the following items are shown: the hallmark(s) for which it was selected, and the number of other hallmarks with which it has complementary relationships, contrary relationships, no known relationships and controversial relationships. For targets that have contrary relationships, the conflicted hallmark(s) are shown. Totals and percentages of each type of relationship are shown at the end of the table.
AN = Angiogenesis, AP = Resistance to Apoptosis, DM = Dysregulated Metabolism, EAG = Evasion of Anti-Growth Signaling, GI = Genomic Instability, IE = Immune Evasion, RI = Replicative Immortality, SPS = Sustained Proliferative Signaling, TIM = Tissue Invasion and Metastasis, TME = Tumor Microenvironment, TPI = Tumor Promoting Inflammation.